QGel

Team

Executive Management

Dr. Colin Sanctuary
Chief Executive Officer, Board Member & Founder

Colin is a Biomedical Engineer and he held positions at Straumann and Medtronic before founding QGel in 2009.

Dr. Simone Rizzi
Chief Scientific Officer

Simone is a Biomaterials Engineer and specialist in QGel’s technology. He joined QGel at its inception in 2009 and leads QGel’s lab operations and product development activities.

Prof. Matthias Lütolf
co-founder

Matthias is one of the original inventors of initial technology behind QGel and is a professor and director of the Institute of Bioengineering at the Swiss Federal Institute of Technology.

Lab & Facilities

QGel Manufacturing Facility

Production of QGel® Vials and Assay Kits is done at our facility and high-quality grade raw materials are used to ensure optimal product reproducibility.

QGel Biochemistry Labs

Innovation and development of QGel extracellular microenvironments for specific targets and cancer-types is done in-house by qualified scientists.

QGel Biology Labs

All assays at QGel are developed and validated for automated laboratory systems. The high-throughput screening facility at QGel consists of liquid-handling robots, high-content imaging, plate readers, gene-expression devices and more.

QGel Lab & Facilities

At QGel we have the infrastructure and staff to develop cell-based assays from A to Z. Combined with our unique manufacturing capabilities for custom-designed cancer microenvironments, this makes QGel’s facility a one-of-a-kind facility to innovate and develop target-specific cell-based assays based on QGel’s innovative hydrogel technology.

QGel staff is a mix of highly qualified and enthusiastic biologists, life sciences engineers, biochemists and materials scientists.

All operations, whether for product development, manufacturing or assay development, are executed diligently and with client quality expectations in mind. QGel employees understand the importance of scientific method in assay development, and the importance delivering results and products to our clients based on solid scientific evidence.

If you are interested in developing an assay with us and you would like to visit our facility, please contact us to arrange for a tour of our facility in Lausanne, Switzerland.

Partnering with QGel

QGel Partnering

QGel Partnering

Schedule a presentation

If you would like to learn more, we would be happy to meet you in person or by webinar. Please contact us and we will be in touch with you rapidly to setup a call.

Download our Slide Deck

For a non-confidential slide-deck for you to examine QGel in more detail, please contact us, and we will get back to you as soon as possible.

QGel’s Business Model

Our clients turn to QGel when they are faced with problems in drug development. A successful QGel solution is embodied in the form of a product: a custom-designed QGel® Assay Kit.

Any scientist working in drug development are faced with challenges every day. For this reason, partnerships with QGel are based on concrete success-milestones. This means that QGel helps to solve a challenging problem, and the client only commits once QGel achieves the client specific success-milestone. Typical milestones could be, for example, the expression of your target in a specific cancer type, or perhaps the activation of T-cells in a QGel cancer microenvironment.

A success-milestone fee would include a first batch of QGel® Assay Kits for the client to use at their screening facility. To help integrate QGel® Assay Kits into your workflows, QGel scientists offer on-site training so that you can learn from our experience. This way, your assay is rapidly operational and you can focus on drug development, instead of translating the assay to work.

QGel also partners with vendors of laboratory automation systems. If you are a vendor, and would like to learn more about QGel workflows, please contact us.

QGel Partnering

QGel’s Business Model

Our clients turn to QGel when they are faced with problems in drug development. A successful QGel solution is embodied in the form of a product: a custom-designed QGel® Assay Kit.

Any scientist working in drug development are faced with challenges every day. For this reason, partnerships with QGel are based on concrete success-milestones. This means that QGel helps to solve a challenging problem, and the client only is commits once QGel achieves the client specific success-milestone. Typical milestones could be, for example, the expression of your target in a specific cancer type, or perhaps the activation of T-cells in a QGel cancer microenvironment.

A success-milestone fee would include a first batch of QGel® Assay Kits for the client to use at their screening facility. To help integrate QGel® Assay Kits into your workflows, QGel scientists offer on-site training so that you can learn from our experience. This way, your assay is rapidly operational and you can focus on drug development, instead of translating the assay to work.

QGel also partners with vendors of laboratory automation systems. If you are a vendor, and would like to learn more about QGel workflows, please contact us.

QGel Partnering

Schedule a presentation

If you would like to learn more, we would be happy to meet you in person or by webinar. Please contact us and we will be in touch with you rapidly to setup a call.

QGel Partnering

Download our Slide Deck

For a non-confidential slide-deck for you to examine QGel in more detail, please contact us, and we will get back to you as soon as possible.

Contact us

Contact me about QGel for Organoids
Contact me about in vivo applications
Help me design a study with QGel products
I want to place an order
After-sales support
Contact me, I have questions

QGel SA
Innovation Park
EPFL Building G
1015 Lausanne, Switzerland
T +41 21 694 0707
F +41 21 560 4957

Print Directions
Google Maps

Innovating Drug Discovery
QGel enables drug development in a laboratory environment that accurately and reliably mimics the functioning of human organs, which means greater predictability of drug efficacy before the clinical phase. With an improved understanding of a drug’s potential, researchers spend more time and resources on the most promising therapies.

Innovating Diagnostics
QGel diagnostic tools test drug efficacy directly on tumor cells reproduced from biopsy, which means patients gain access to therapies tailored specifically to their disease. QGel advances patient outcomes, promoting personalised and accelerated treatments in an economically sustainable way.

Contact us

Sitemap | Privacy Policy | Legal Notice
© 2015 QGel SA, Lausanne, Switzerland
  • QGel on Twitter
  • QGel on LinkedIn
  • QGel on Vimeo
Unless otherwise specified, all product names appearing in this website are trademarks owned by or licensed to QGel Inc. Unauthorized use is prohibited.